Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study

References

• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087–1097.
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1098–1107.
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Mar;13(3):247–256.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LME, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler J. 2014 May;20(6):705–716.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 Oct 6;365(14):1293–1303.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun;13(6):545–556.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):387–401.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):402–415.
   PubMed Web of Science ®Google Scholar
• Genzyme S. A division of Sanofi-Aventis Canada Inc. aubagio teriflunomide tablets 14mg product monograph 2017. 2017 January 25th [cited 2020 Jun 1st]. Available from: https://pdf.hres.ca/dpd_pm/00038165.PDF
   Google Scholar
• Marrie RA, Miller A, Sormani MP, et al. The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology. 2016 Apr 12;86(15):1437–1445.
   PubMed Web of Science ®Google Scholar
• BC Ministry of Health [creator] (2016): PharmaNet. V2. BC ministry of health [publisher]. Data Extract. Data Stewardship Committee (http://www.popdata.bc.ca/data
   Google Scholar
• Lifelabs Medical Laboratory Services. Lifelabs Medical Laboratory Services [creator] (2018): Lifelabs laboratory data. population data BC [publisher]. Data Extract. (2018).
   Google Scholar
• Providence Health Care BC. Providence Health Care BC [creator] (2018): Laboratory data. population data BC [publisher]. Data Extract. (2018). http://www.popdata.bc.ca/data.
   Google Scholar
• Children’s and Women’s Health Centre of BC. Children’s and Women’s Health Centre of BC [creator] (2018): Laboratory data. Population data BC [publisher]. Data extract. (2018). http://www.popdata.bc.ca/data
   Google Scholar
• Vancouver Coastal, Fraser, Vancouver Island, Northern, and Interior, BC Health Authorities [creator]: Laboratory Data. Population Data BC [publisher]. Data Extract. (2018). http://www.popdata.bc.ca/data
   Google Scholar
• Marriott JJ, Chen H, Fransoo R, et al. Validation of an algorithm to detect severe MS relapses in administrative health databases. Mult Scler Relat Disord. 2018 Jan;19:134–139.
   PubMed Web of Science ®Google Scholar
• British Columbia Ministry of Health [creator] [2016]. Medical services plan (MSP) Payment information file. V2. Population data BC [publisher]. Data Extract MOH. 2016 http://www.popdata.bc.ca/data
   Google Scholar
• Canadian Institute for Health Information [creator] [2016]. Discharge abstract database (Hospital Separations). V2. Population data BC [publisher]. Data extract MOH. 2016 http://www.popdata.bc.ca/data
   Google Scholar
• British Columbia Ministry of Health [creator] [2016]. Consolidation file (MSP registration & premium billing). V2. Population data BC [publisher]. Data extract MOH, 2016. 2016 http://www.popdata.bc.ca/data
   Google Scholar
• Wilkins R, Khan S PDDF+ version 5H User’s guide. Automated geographic coding based on the statistics Canada postal code conversion files, including postal codes through October 2010. Statistics Canada, Catalogue 82F0086-XDB 2010.
   Google Scholar
• BC Vital Statistics Agency [creator] (2016). Vital statistics deaths. V2. Population Data BC [publisher]. Data extract BC Vital statistics agency. 2016 http://www.popdata.bc.ca/data
   Google Scholar
• Novartis Pharmaceuticals Canada Inc. GILENYA (Fingolimod capsules 0.25mg and 0.5 mg) Product Monograph 2011, December 19th 2019 [cited 2020 Jun 1st]; Available from: https://www.novartis.ca/en/our-products/pharmaceuticals#ui-id–1=6
   Google Scholar
• Biogen Canada Inc. TECFIDERA®Dimethyl fumarate delayed-release capsules 120 mg and 240 mg product mongraph 2013, November 28th 2019 [cited 2020 Jun 1st]; Available from: https://www.biogen.ca/content/dam/corporate/en_CA/pdfs/products/TECFIDERA/TECFIDERA_PM_EN_28Nov2019.pdf
   Google Scholar
• Ng HS, Kingwell E, Zhu F, et al. Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study. Mult Scler. 2020;6:1352458520910500.
   Google Scholar
• U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) Version 5.0. Published: November 27, 2017. U.S. Department of Health and Human Services 2017:155.
   Google Scholar
• Drahos J, Vanwormer JJ, Greenlee RT, et al. Accuracy of ICD-9-CM codes in identifying infections of pneumonia and herpes simplex virus in administrative data. Ann Epidemiol. 2013 May;23(5):291–293.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Yu BN, Leung S, et al. Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler. 2012 Feb 10;18:1310–1319.
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992 Jun;45(6):613–619.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Seemuller S, Zhao Y, et al. Liver test abnormalities in multiple sclerosis: findings from placebo-treated patients. Neurology. 2006Oct10;67(7):1291–1293.
   PubMed Web of Science ®Google Scholar
• Rastas C, Sirignano D, Barner A, et al. Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis. J Neurol. 2019 Nov;266(11):2867–2868.
   PubMed Web of Science ®Google Scholar
• Brandstadter R, Katz Sand I. ECTRIMS ePosters: A case of Legionnaires’ disease in a patient on dimethyl fumarate therapy for relapsing-remitting multiple sclerosis [EP1656]. MSParis 2017. Mult Scler J. 2017;23:Suppl.3:871. [Abstract]
   Google Scholar
• Gieselbach RJ, Muller-Hansma AH, Wijburg MT, et al. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol. 2017 Jun;264(6):1155–1164.
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Naismith RT, Parks BJ, et al. Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin. 2015 Jan-Dec; 1;21:796–797.
   Google Scholar
• Smoot K, Spinelli KJ, Stuchiner T, et al. Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center. Mult Scler. 2018 Jun;24(7):942–950.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Oger J. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol. 2004 Nov;251(11):1297–1303.
   PubMed Web of Science ®Google Scholar
• Manni A, Direnzo V, Iaffaldano A, et al. Gender differences in safety issues during Fingolimod therapy: evidence from a real-life relapsing multiple Sclerosis cohort. Brain Behav. 2017 Oct;7(10):e00804.
   PubMed Web of Science ®Google Scholar
• Chan S, Kingwell E, Oger J, et al. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: A longitudinal study. Mult Scler. 2011 Dec 10;17(3):361–367.
   PubMed Web of Science ®Google Scholar
• Francis GS, Grumser Y, Alteri E, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf. 2003;26(11):815–827.
   PubMed Web of Science ®Google Scholar
• Kariv R, Leshno M, Beth-Or A, et al. Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int. 2006 May;26(4):445–450.
   PubMed Web of Science ®Google Scholar
• Dufour DR, Lott JA, Nolte FS, et al. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem. 2000 Dec;46(12):2027–2049.
   PubMed Web of Science ®Google Scholar
• Akbulak RO, Rosenkranz SC, Schaeffer BN, et al. Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis. Mult Scler Relat Disord. 2018 Jan;19:44–49.
   PubMed Web of Science ®Google Scholar
• Simula S, Laitinen T, Laitinen TM, et al. Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis. Mult Scler. 2016 Jul;22(8):1080–1085.
   PubMed Web of Science ®Google Scholar
• Lindsey JW, Haden-Pinneri K, Memon NB, et al. Sudden unexpected death on fingolimod. Mult Scler. 2012 Oct;18(10):1507–1508.
   PubMed Web of Science ®Google Scholar
• Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017 Feb;23(2):253–265.
   PubMed Web of Science ®Google Scholar
• Tu K, Nieuwlaat R, Cheng SY, et al. Identifying patients with atrial fibrillation in administrative data. Can J Cardiol. 2016 Dec;32(12):1561–1565.
   PubMed Web of Science ®Google Scholar
• Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying ventricular arrhythmias using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012 Jan;21(Suppl 1):148–153.
   PubMedGoogle Scholar
• Ayrignac X, Bilodeau PA, Prat A, et al. Assessing the risk of multiple sclerosis disease-modifying therapies. Expert Rev Neurother. 2019 Jul;19(7):695–706.
   PubMed Web of Science ®Google Scholar